Gilead Acquires Arcellx to Lead the Future of Multiple Myeloma Cell Therapy

In a blockbuster move to revitalize its oncology pipeline, Gilead Sciences has announced a definitive agreement to acquire its longtime development partner, Arcellx, in a transaction valued at $7.8 billion.

Under the terms of the deal, which is expected to close in the second quarter of 2026, Gilead will pay $115 per share for the remaining stock of Arcellx it did not already own, representing a massive 79% premium. Arcellx stockholders could also receive an additional $5 per share contingent upon specific future sales milestones. Following the announcement, Arcellx shares skyrocketed by 78%, marking their best day on record.

The crown jewel of this acquisition is "anito-cel," an experimental multiple myeloma cell therapy currently under review by the Food and Drug Administration. The treatment modifies the body's immune T-cells to hunt and kill multiple myeloma, a progressive cancer of the bone marrow.

For Gilead, this $7.8 billion wager is a strategic necessity. The company's cell therapy business recently reported a 7% decline in overall sales and predicted a further 10% slide. Anito-cel could be the catalyst needed to turn this division around. Clinical trial results have shown a remarkable 96% response rate among patients whose cancer had relapsed or failed to respond to at least three prior treatments. Furthermore, Gilead anticipates that anito-cel will offer a better safety profile—specifically a lower risk of parkinsonism—compared to existing rival therapies from Johnson & Johnson and Bristol Myers Squibb.

Gilead’s CEO, Daniel O’Day, emphasized that anito-cel has the potential to become a "foundational treatment" for the disease, allowing the company to enter a highly lucrative $12 billion market for relapsed and refractory multiple myeloma.

This acquisition mirrors Gilead's $12 billion purchase of Kite Pharma nearly a decade ago, which established its initial foothold in cancer cell therapy. It also underscores a broader pharmaceutical industry trend of investing heavily in "living drugs," echoing Eli Lilly's recent $2.4 billion acquisition of the cell therapy biotech Orna Therapeutics.

---

🔖 Sources

Gilead to buy Arcellx in $7.8B wager on multiple myeloma cell therapy

This Biotech Stock Is Having Its Best Day Ever. Gilead Sciences Is Buying It

---

Keywords: Multiple Myeloma Cell Therapy

Multiple Myeloma Cell Therapy

---